Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib

被引：6
|
作者：
Lisa Hutchinson
机构：
来源：
Nature Reviews Clinical Oncology | 2010年 / 7卷 / 8期
关键词：
D O I：
10.1038/nrclinonc.2010.113
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：424 / 424
相关论文
共 50 条
  • [1] Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
    O'Brien, Neil A.
    Browne, Brigid C.
    Chow, Lucy
    Wang, Yuhua
    Ginther, Charles
    Arboleda, Jane
    Duffy, Michael J.
    Crown, John
    O'Donovan, Norma
    Slamon, Dennis J.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) : 1489 - 1502
  • [2] The Role of MAPK and PI3K/AKT/mTOR Signaling in Innate Lapatinib Resistance
    McDermott, M.
    O'Brien, N.
    McDonald, K.
    Crown, J.
    O'Donovan, N.
    Slamon, D.
    CANCER RESEARCH, 2011, 71
  • [3] PI3K/Akt pathway alterations as a mechanism of resistance to trastuzumab in breast cancer
    Fernandez Garcia, M. S.
    Centeno Ramos, I.
    Garcia Pravia, C.
    Balbin Felechosa, M.
    Fresno Forcelledo, M. F.
    VIRCHOWS ARCHIV, 2011, 459 : S70 - S70
  • [4] An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib
    Hu, X.
    Wang, L. P.
    Zhang, Q. L.
    Zhang, J.
    Guo, H. Y.
    Sun, S.
    Wang, B. Y.
    Jia, Z.
    Shao, Z. M.
    Wang, Z. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib (vol 9, pg 1489, 2010)
    O'Brien, N. A.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2211 - 2211
  • [6] PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia
    Kong, Chunfang
    Wu, Mei
    Lu, Qilin
    Ke, Bo
    Xie, Jianhui
    Li, Anna
    LEUKEMIA RESEARCH, 2024, 144
  • [7] PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
    Leiping Wang
    Qunling Zhang
    Jian Zhang
    Si Sun
    Haiyi Guo
    Zhen Jia
    Biyun Wang
    Zhimin Shao
    Zhonghua Wang
    Xichun Hu
    BMC Cancer, 11
  • [8] PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
    Wang, Leiping
    Zhang, Qunling
    Zhang, Jian
    Sun, Si
    Guo, Haiyi
    Jia, Zhen
    Wang, Biyun
    Shao, Zhimin
    Wang, Zhonghua
    Hu, Xichun
    BMC CANCER, 2011, 11
  • [9] Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway
    Chen, Xi
    Wang, Han
    Ou-yang, Xue-nong
    Xie, Fang-wei
    Wu, Jing-jing
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2013, 17 (04): : 363 - 369
  • [10] AKT-INDEPENDENT SGK1 SIGNALING CONFERS RESISTANCE TO PI3K INHIBITION
    不详
    CANCER DISCOVERY, 2016, 6 (09) : 942 - 942
12345